- Bristol-Myers Squibb Co BMY is planning to tender its shares in Acceleron Pharma Inc XLRN after Merck & Co Inc MRK agreed to buy the biotechnology company for $11.5 billion, Bloomberg reported citing people with knowledge of the matter.
- Bristol-Myers holds an 11.5% stake in Acceleron. Selling the stake will bring the Merck deal closer to completion.
- Another Acceleron investor, Avoro Capital, which holds about 7% of Acceleron’s stock, said Merck’s deal “drastically undervalues” Acceleron.
- Related: Activist Investor Thinks Merck Undervalues Acceleron Buy.
- Hedge fund Darwin Global, which owns 3.8% of Acceleron’s stock, urged shareholders not to tender their shares.
- Darwin Global Management also said Acceleron execs have settled for a price that was far too low.
- By Darwin’s math released Wednesday, the deal undervalues Acceleron by as much as $17 billion, given the blockbuster prospects of both Reblozyl and sotatercept.
- Another shareholder, Holocene Advisors, said last week that it didn’t plan to tender its shares.
- Price Action: XLRN shares are up 0.67% at $173.66, BMY shares are down 0.89% at $57.56 during the market session on the last check Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.